Angstrom Bio leverages third-generation sequencing to develop new classes of information-rich, sequencing-based molecular diagnostics. Angstrom's AMPD platform, which was validated in collaboration with the Walter Reed Army Institute of Research, employs proprietary PCR chemistry and bioinformatics to enable the use of nanopore third-generation genome sequencers for the analysis of diagnostic samples.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/17/21 | $3,000,000 |
GreyBird Ventures | undisclosed |
